25 XP   0   0   10

Amplia Therapeutics Ltd
Buy, Hold or Sell?

Let's analyse Amplia Therapeutics Ltd together

PenkeI guess you are interested in Amplia Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Amplia Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Amplia Therapeutics Ltd

I send you an email if I find something interesting about Amplia Therapeutics Ltd.

Quick analysis of Amplia Therapeutics Ltd (30 sec.)










What can you expect buying and holding a share of Amplia Therapeutics Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
A$0.08
Expected worth in 1 year
A$-0.04
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
A$-0.12
Return On Investment
-203.2%

For what price can you sell your share?

Current Price per Share
A$0.06
Expected price per share
A$0 - A$0.068
How sure are you?
50%

1. Valuation of Amplia Therapeutics Ltd (5 min.)




Live pricePrice per Share (EOD)

A$0.06

Intrinsic Value Per Share

A$-0.36 - A$-0.22

Total Value Per Share

A$-0.28 - A$-0.14

2. Growth of Amplia Therapeutics Ltd (5 min.)




Is Amplia Therapeutics Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$10.1m$13.9m-$3.8m-38.0%

How much money is Amplia Therapeutics Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$3.9m-$2.3m-$1.6m-41.6%
Net Profit Margin-524.8%-183.7%--

How much money comes from the company's main activities?

3. Financial Health of Amplia Therapeutics Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#687 / 1019

Most Revenue
#527 / 1019

Most Profit
#388 / 1019

Most Efficient
#754 / 1019

What can you expect buying and holding a share of Amplia Therapeutics Ltd? (5 min.)

Welcome investor! Amplia Therapeutics Ltd's management wants to use your money to grow the business. In return you get a share of Amplia Therapeutics Ltd.

What can you expect buying and holding a share of Amplia Therapeutics Ltd?

First you should know what it really means to hold a share of Amplia Therapeutics Ltd. And how you can make/lose money.

Speculation

The Price per Share of Amplia Therapeutics Ltd is A$0.061. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Amplia Therapeutics Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Amplia Therapeutics Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.08. Based on the TTM, the Book Value Change Per Share is A$-0.03 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.06 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Amplia Therapeutics Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.02-33.8%-0.02-33.8%-0.01-19.7%-0.01-17.6%-0.01-22.9%
Usd Book Value Change Per Share-0.02-32.5%-0.02-32.5%0.0462.3%0.0114.6%0.002.5%
Usd Dividend Per Share0.000.0%0.000.0%0.0586.6%0.0117.3%0.018.7%
Usd Total Gains Per Share-0.02-32.5%-0.02-32.5%0.09148.9%0.0231.9%0.0111.2%
Usd Price Per Share0.05-0.05-0.09-0.09-0.13-
Price to Earnings Ratio-2.64--2.64--7.72--10.04--9.49-
Price-to-Total Gains Ratio-2.74--2.74-1.02--28.89--16.95-
Price to Book Ratio1.04-1.04-1.29-2.24-5.66-
Price-to-Total Gains Ratio-2.74--2.74-1.02--28.89--16.95-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0390644
Number of shares25598
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.020.01
Usd Total Gains Per Share-0.020.02
Gains per Quarter (25598 shares)-508.01498.17
Gains per Year (25598 shares)-2,032.031,992.68
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-2032-204210829111983
20-4064-4074216418213976
30-6096-6106324627325969
40-8128-8138432836437962
50-10160-10170541045539955
60-12192-122026492546411948
70-14224-142347574637413941
80-16256-162668656728515934
90-18288-182989738819617927
100-20320-2033010820910619920

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.010.04.00.0%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%4.06.00.040.0%7.07.00.050.0%
Dividend per Share0.00.01.00.0%1.00.02.033.3%1.00.04.020.0%1.00.09.010.0%1.00.013.07.1%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%4.06.00.040.0%7.07.00.050.0%

Fundamentals of Amplia Therapeutics Ltd

About Amplia Therapeutics Ltd

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for acute myeloid leukemia (AML) and certain solid tumors.It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Fundamental data was last updated by Penke on 2024-03-28 18:39:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Amplia Therapeutics Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Amplia Therapeutics Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Amplia Therapeutics Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of -524.8% means that $-5.25 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Amplia Therapeutics Ltd:

  • The MRQ is -524.8%. The company is making a huge loss. -2
  • The TTM is -524.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-524.8%TTM-524.8%0.0%
TTM-524.8%YOY-183.7%-341.1%
TTM-524.8%5Y-2,209.4%+1,684.6%
5Y-2,209.4%10Y-2,959.5%+750.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-524.8%-197.2%-327.6%
TTM-524.8%-210.4%-314.4%
YOY-183.7%-279.3%+95.6%
5Y-2,209.4%-436.8%-1,772.6%
10Y-2,959.5%-599.3%-2,360.2%
1.1.2. Return on Assets

Shows how efficient Amplia Therapeutics Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Amplia Therapeutics Ltd to the Biotechnology industry mean.
  • -33.4% Return on Assets means that Amplia Therapeutics Ltd generated $-0.33 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Amplia Therapeutics Ltd:

  • The MRQ is -33.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -33.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-33.4%TTM-33.4%0.0%
TTM-33.4%YOY-14.9%-18.5%
TTM-33.4%5Y-22.8%-10.6%
5Y-22.8%10Y-61.1%+38.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-33.4%-13.6%-19.8%
TTM-33.4%-12.9%-20.5%
YOY-14.9%-11.9%-3.0%
5Y-22.8%-14.2%-8.6%
10Y-61.1%-16.2%-44.9%
1.1.3. Return on Equity

Shows how efficient Amplia Therapeutics Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Amplia Therapeutics Ltd to the Biotechnology industry mean.
  • -39.4% Return on Equity means Amplia Therapeutics Ltd generated $-0.39 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Amplia Therapeutics Ltd:

  • The MRQ is -39.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -39.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-39.4%TTM-39.4%0.0%
TTM-39.4%YOY-16.7%-22.7%
TTM-39.4%5Y-25.1%-14.3%
5Y-25.1%10Y-69.1%+44.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-39.4%-17.0%-22.4%
TTM-39.4%-16.1%-23.3%
YOY-16.7%-15.4%-1.3%
5Y-25.1%-20.0%-5.1%
10Y-69.1%-21.1%-48.0%

1.2. Operating Efficiency of Amplia Therapeutics Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Amplia Therapeutics Ltd is operating .

  • Measures how much profit Amplia Therapeutics Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Amplia Therapeutics Ltd to the Biotechnology industry mean.
  • An Operating Margin of -628.5% means the company generated $-6.28  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Amplia Therapeutics Ltd:

  • The MRQ is -628.5%. The company is operating very inefficient. -2
  • The TTM is -628.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-628.5%TTM-628.5%0.0%
TTM-628.5%YOY-283.7%-344.7%
TTM-628.5%5Y-2,294.1%+1,665.6%
5Y-2,294.1%10Y-3,022.6%+728.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-628.5%-286.1%-342.4%
TTM-628.5%-224.4%-404.1%
YOY-283.7%-288.4%+4.7%
5Y-2,294.1%-475.2%-1,818.9%
10Y-3,022.6%-624.7%-2,397.9%
1.2.2. Operating Ratio

Measures how efficient Amplia Therapeutics Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 6.28 means that the operating costs are $6.28 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Amplia Therapeutics Ltd:

  • The MRQ is 6.285. The company is inefficient in keeping operating costs low. -1
  • The TTM is 6.285. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ6.285TTM6.2850.000
TTM6.285YOY2.837+3.447
TTM6.2855Y23.835-17.551
5Y23.83510Y32.233-8.398
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.2852.997+3.288
TTM6.2853.247+3.038
YOY2.8373.766-0.929
5Y23.8355.675+18.160
10Y32.2337.857+24.376

1.3. Liquidity of Amplia Therapeutics Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Amplia Therapeutics Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.82 means the company has $3.82 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Amplia Therapeutics Ltd:

  • The MRQ is 3.821. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.821. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.821TTM3.8210.000
TTM3.821YOY31.183-27.363
TTM3.8215Y9.026-5.206
5Y9.02610Y9.740-0.714
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8213.930-0.109
TTM3.8214.251-0.430
YOY31.1835.436+25.747
5Y9.0266.045+2.981
10Y9.7406.363+3.377
1.3.2. Quick Ratio

Measures if Amplia Therapeutics Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Amplia Therapeutics Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 3.78 means the company can pay off $3.78 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Amplia Therapeutics Ltd:

  • The MRQ is 3.783. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.783. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.783TTM3.7830.000
TTM3.783YOY31.030-27.247
TTM3.7835Y8.951-5.168
5Y8.95110Y10.423-1.472
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7833.629+0.154
TTM3.7834.065-0.282
YOY31.0305.397+25.633
5Y8.9515.993+2.958
10Y10.4236.277+4.146

1.4. Solvency of Amplia Therapeutics Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Amplia Therapeutics Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Amplia Therapeutics Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15 means that Amplia Therapeutics Ltd assets are financed with 15.2% credit (debt) and the remaining percentage (100% - 15.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Amplia Therapeutics Ltd:

  • The MRQ is 0.152. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.152. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.152TTM0.1520.000
TTM0.152YOY0.108+0.045
TTM0.1525Y0.085+0.068
5Y0.08510Y0.098-0.013
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1520.332-0.180
TTM0.1520.334-0.182
YOY0.1080.268-0.160
5Y0.0850.366-0.281
10Y0.0980.390-0.292
1.4.2. Debt to Equity Ratio

Measures if Amplia Therapeutics Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Amplia Therapeutics Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 18.0% means that company has $0.18 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Amplia Therapeutics Ltd:

  • The MRQ is 0.180. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.180. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.180TTM0.1800.000
TTM0.180YOY0.121+0.059
TTM0.1805Y0.095+0.085
5Y0.09510Y0.112-0.017
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1800.381-0.201
TTM0.1800.390-0.210
YOY0.1210.334-0.213
5Y0.0950.434-0.339
10Y0.1120.466-0.354

2. Market Valuation of Amplia Therapeutics Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Amplia Therapeutics Ltd generates.

  • Above 15 is considered overpriced but always compare Amplia Therapeutics Ltd to the Biotechnology industry mean.
  • A PE ratio of -2.64 means the investor is paying $-2.64 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Amplia Therapeutics Ltd:

  • The EOD is -1.896. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.642. Based on the earnings, the company is expensive. -2
  • The TTM is -2.642. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.896MRQ-2.642+0.746
MRQ-2.642TTM-2.6420.000
TTM-2.642YOY-7.719+5.078
TTM-2.6425Y-10.035+7.394
5Y-10.03510Y-9.492-0.543
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.896-2.315+0.419
MRQ-2.642-2.560-0.082
TTM-2.642-2.664+0.022
YOY-7.719-4.122-3.597
5Y-10.035-6.258-3.777
10Y-9.492-6.108-3.384
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Amplia Therapeutics Ltd:

  • The EOD is -2.230. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.107. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.107. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.230MRQ-3.107+0.877
MRQ-3.107TTM-3.1070.000
TTM-3.107YOY-6.370+3.262
TTM-3.1075Y-11.318+8.211
5Y-11.31810Y-12.440+1.122
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.230-3.067+0.837
MRQ-3.107-3.251+0.144
TTM-3.107-3.545+0.438
YOY-6.370-5.595-0.775
5Y-11.318-8.315-3.003
10Y-12.440-8.708-3.732
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Amplia Therapeutics Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.04 means the investor is paying $1.04 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Amplia Therapeutics Ltd:

  • The EOD is 0.747. Based on the equity, the company is cheap. +2
  • The MRQ is 1.041. Based on the equity, the company is underpriced. +1
  • The TTM is 1.041. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.747MRQ1.041-0.294
MRQ1.041TTM1.0410.000
TTM1.041YOY1.288-0.246
TTM1.0415Y2.244-1.203
5Y2.24410Y5.655-3.411
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.7471.905-1.158
MRQ1.0412.111-1.070
TTM1.0412.095-1.054
YOY1.2882.836-1.548
5Y2.2443.443-1.199
10Y5.6553.794+1.861
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Amplia Therapeutics Ltd.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Amplia Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.031-0.0310%0.059-152%0.014-323%0.002-1407%
Book Value Per Share--0.0820.0820%0.113-28%0.067+21%0.048+70%
Current Ratio--3.8213.8210%31.183-88%9.026-58%9.740-61%
Debt To Asset Ratio--0.1520.1520%0.108+42%0.085+80%0.098+56%
Debt To Equity Ratio--0.1800.1800%0.121+49%0.095+90%0.112+61%
Dividend Per Share----0%0.083-100%0.017-100%0.008-100%
Eps---0.032-0.0320%-0.019-42%-0.017-48%-0.022-32%
Free Cash Flow Per Share---0.027-0.0270%-0.023-17%-0.016-41%-0.018-32%
Free Cash Flow To Equity Per Share---0.028-0.0280%0.066-142%0.007-486%0.007-514%
Gross Profit Margin--1.0831.0830%1.059+2%1.104-2%1.052+3%
Intrinsic Value_10Y_max---0.219--------
Intrinsic Value_10Y_min---0.364--------
Intrinsic Value_1Y_max---0.017--------
Intrinsic Value_1Y_min---0.026--------
Intrinsic Value_3Y_max---0.056--------
Intrinsic Value_3Y_min---0.087--------
Intrinsic Value_5Y_max---0.099--------
Intrinsic Value_5Y_min---0.159--------
Market Cap11834366.000-39%16490510.00016490510.0000%28130870.000-41%25938602.200-36%38723597.600-57%
Net Profit Margin---5.248-5.2480%-1.837-65%-22.094+321%-29.595+464%
Operating Margin---6.285-6.2850%-2.837-55%-22.941+265%-30.226+381%
Operating Ratio--6.2856.2850%2.837+122%23.835-74%32.233-81%
Pb Ratio0.747-39%1.0411.0410%1.288-19%2.244-54%5.655-82%
Pe Ratio-1.896+28%-2.642-2.6420%-7.719+192%-10.035+280%-9.492+259%
Price Per Share0.061-39%0.0850.0850%0.145-41%0.134-36%0.200-57%
Price To Free Cash Flow Ratio-2.230+28%-3.107-3.1070%-6.370+105%-11.318+264%-12.440+300%
Price To Total Gains Ratio-1.968+28%-2.743-2.7430%1.022-368%-28.892+953%-16.947+518%
Quick Ratio--3.7833.7830%31.030-88%8.951-58%10.423-64%
Return On Assets---0.334-0.3340%-0.149-55%-0.228-32%-0.611+83%
Return On Equity---0.394-0.3940%-0.167-58%-0.251-36%-0.691+75%
Total Gains Per Share---0.031-0.0310%0.142-122%0.030-202%0.011-392%
Usd Book Value--10141070.85010141070.8500%13991227.375-28%8362773.933+21%5951132.238+70%
Usd Book Value Change Per Share---0.020-0.0200%0.038-152%0.009-323%0.002-1407%
Usd Book Value Per Share--0.0520.0520%0.072-28%0.043+21%0.031+70%
Usd Dividend Per Share----0%0.053-100%0.011-100%0.005-100%
Usd Eps---0.021-0.0210%-0.012-42%-0.011-48%-0.014-32%
Usd Free Cash Flow---3398807.088-3398807.0880%-2828276.008-17%-2013887.269-41%-2295645.082-32%
Usd Free Cash Flow Per Share---0.018-0.0180%-0.015-17%-0.010-41%-0.012-32%
Usd Free Cash Flow To Equity Per Share---0.018-0.0180%0.042-142%0.005-486%0.004-514%
Usd Market Cap7578727.986-39%10560522.60410560522.6040%18015009.148-41%16611080.849-36%24798591.903-57%
Usd Price Per Share0.039-39%0.0540.0540%0.093-41%0.086-36%0.128-57%
Usd Profit---3997655.374-3997655.3740%-2333756.567-42%-2082226.915-48%-2709293.531-32%
Usd Revenue--761746.834761746.8340%1270115.566-40%613633.842+24%614156.984+24%
Usd Total Gains Per Share---0.020-0.0200%0.091-122%0.019-202%0.007-392%
 EOD+3 -5MRQTTM+0 -0YOY+3 -335Y+10 -2610Y+13 -23

4.2. Fundamental Score

Let's check the fundamental score of Amplia Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.896
Price to Book Ratio (EOD)Between0-10.747
Net Profit Margin (MRQ)Greater than0-5.248
Operating Margin (MRQ)Greater than0-6.285
Quick Ratio (MRQ)Greater than13.783
Current Ratio (MRQ)Greater than13.821
Debt to Asset Ratio (MRQ)Less than10.152
Debt to Equity Ratio (MRQ)Less than10.180
Return on Equity (MRQ)Greater than0.15-0.394
Return on Assets (MRQ)Greater than0.05-0.334
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Amplia Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.630
Ma 20Greater thanMa 500.077
Ma 50Greater thanMa 1000.077
Ma 100Greater thanMa 2000.078
OpenGreater thanClose0.070
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in AUD. All numbers in thousands.

Summary
Total Assets18,684
Total Liabilities2,849
Total Stockholder Equity15,836
 As reported
Total Liabilities 2,849
Total Stockholder Equity+ 15,836
Total Assets = 18,684

Assets

Total Assets18,684
Total Current Assets10,509
Long-term Assets8,176
Total Current Assets
Cash And Cash Equivalents 9,257
Net Receivables 1,148
Other Current Assets 103
Total Current Assets  (as reported)10,509
Total Current Assets  (calculated)10,509
+/-0
Long-term Assets
Property Plant Equipment 185
Intangible Assets 7,938
Long-term Assets Other 53
Long-term Assets  (as reported)8,176
Long-term Assets  (calculated)8,176
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,751
Long-term Liabilities98
Total Stockholder Equity15,836
Total Current Liabilities
Short-term Debt 2,175
Short Long Term Debt 2,107
Accounts payable 347
Other Current Liabilities 229
Total Current Liabilities  (as reported)2,751
Total Current Liabilities  (calculated)4,857
+/- 2,107
Long-term Liabilities
Long term Debt Total 95
Other Liabilities 4
Long-term Liabilities  (as reported)98
Long-term Liabilities  (calculated)98
+/- 0
Total Stockholder Equity
Common Stock151,529
Retained Earnings -134,724
Other Stockholders Equity -969
Total Stockholder Equity (as reported)15,836
Total Stockholder Equity (calculated)15,836
+/-0
Other
Capital Stock151,529
Cash And Equivalents7,983
Cash and Short Term Investments 9,257
Common Stock Shares Outstanding 193,975
Current Deferred Revenue-2,181
Liabilities and Stockholders Equity 18,684
Net Debt -6,987
Net Invested Capital 17,942
Net Tangible Assets 7,898
Net Working Capital 7,758
Property Plant and Equipment Gross 263
Short Long Term Debt Total 2,269



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-312012-03-312011-03-312010-03-31
> Total Assets 
10,616
10,647
7,262
11,426
10,176
5,319
5,035
7,537
2,644
9,191
9,116
10,879
24,484
18,684
18,68424,48410,8799,1169,1912,6447,5375,0355,31910,17611,4267,26210,64710,616
   > Total Current Assets 
0
0
0
8,393
7,971
4,624
4,883
7,375
2,644
1,252
1,178
2,936
16,533
10,509
10,50916,5332,9361,1781,2522,6447,3754,8834,6247,9718,393000
       Cash And Cash Equivalents 
1,437
2,821
1,476
8,359
7,942
4,089
3,201
5,763
2,229
1,241
1,108
1,848
14,609
9,257
9,25714,6091,8481,1081,2412,2295,7633,2014,0897,9428,3591,4762,8211,437
       Short-term Investments 
0
0
0
0
0
0
0
4,744
1,933
0
0
0
0
0
000001,9334,7440000000
       Net Receivables 
36
362
49
33
22
26
77
132
244
34
34
1,000
1,843
1,148
1,1481,8431,0003434244132772622334936236
       Inventory 
0
0
0
0
0
0
0
0
0
-34
-35
-999
34
37
3734-999-35-34000000000
   > Long-term Assets 
0
0
0
3,033
2,205
694
151
162
0
7,940
7,939
7,943
7,951
8,176
8,1767,9517,9437,9397,94001621516942,2053,033000
       Property Plant Equipment 
381
305
253
167
161
160
151
162
0
2
1
5
13
185
185135120162151160161167253305381
       Intangible Assets 
8,732
7,095
5,458
2,866
2,044
534
0
0
0
7,938
7,938
7,938
7,938
7,938
7,9387,9387,9387,9387,9380005342,0442,8665,4587,0958,732
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
53
530000000000000
> Total Liabilities 
2,883
2,411
3,223
191
404
453
1,031
908
279
527
511
539
2,636
2,849
2,8492,6365395115272799081,0314534041913,2232,4112,883
   > Total Current Liabilities 
203
246
2,953
191
404
453
1,031
908
279
527
511
539
530
2,751
2,7515305395115272799081,0314534041912,953246203
       Short-term Debt 
0
0
0
0
0
0
0
0
0
11
0
0
2,181
2,175
2,1752,1810011000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
11
0
0
0
2,107
2,10700011000000000
       Accounts payable 
47
61
422
44
90
75
74
88
1
527
474
417
369
347
347369417474527188747590444226147
       Other Current Liabilities 
155
185
186
219
314
378
10
10
278
33
37
122
161
229
22916112237332781010378314219186185155
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
511
2,106
2,106
98
982,1062,1065110000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
2,100
95
952,100000000000000
> Total Stockholder Equity
7,733
8,236
4,039
11,235
9,772
4,866
4,003
6,629
2,364
8,664
8,606
10,340
21,848
15,836
15,83621,84810,3408,6068,6642,3646,6294,0034,8669,77211,2354,0398,2367,733
   Retained Earnings -134,724-128,618-125,207-122,926-120,918-120,305-116,779-109,703-104,760-99,523-105,553000
   Accumulated Other Comprehensive Income 
0
0
0
510
-927
-597
-525
389
-350
-1,363
-1,371
-1,007
-1,042
-969
-969-1,042-1,007-1,371-1,363-350389-525-597-927510000
   Capital Surplus 00000000000000
   Treasury Stock00000000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue1,189
Cost of Revenue-73
Gross Profit1,1161,116
 
Operating Income (+$)
Gross Profit1,116
Operating Expense-7,402
Operating Income-7,475-6,286
 
Operating Expense (+$)
Research Development4,687
Selling General Administrative2,198
Selling And Marketing Expenses517
Operating Expense7,4027,402
 
Net Interest Income (+$)
Interest Income97
Interest Expense-54
Other Finance Cost-0
Net Interest Income43
 
Pretax Income (+$)
Operating Income-7,475
Net Interest Income43
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-7,391-7,560
EBIT - interestExpense = -7,529
-7,391
-6,189
Interest Expense54
Earnings Before Interest and Taxes (EBIT)-7,475-7,337
Earnings Before Interest and Taxes (EBITDA)-7,402
 
After tax Income (+$)
Income Before Tax-7,391
Tax Provision-0
Net Income From Continuing Ops-6,242-7,391
Net Income-6,242
Net Income Applicable To Common Shares-6,242
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses7,475
Total Other Income/Expenses Net84-43
 

Technical Analysis of Amplia Therapeutics Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Amplia Therapeutics Ltd. The general trend of Amplia Therapeutics Ltd is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Amplia Therapeutics Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Amplia Therapeutics Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.062 < 0.065 < 0.068.

The bearish price targets are: .

Tweet this
Amplia Therapeutics Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Amplia Therapeutics Ltd. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Amplia Therapeutics Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Amplia Therapeutics Ltd. The current macd is -0.00077494.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Amplia Therapeutics Ltd price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Amplia Therapeutics Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Amplia Therapeutics Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Amplia Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) ChartAmplia Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Amplia Therapeutics Ltd. The current adx is 23.55.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Amplia Therapeutics Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Amplia Therapeutics Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Amplia Therapeutics Ltd. The current sar is 0.08756.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Amplia Therapeutics Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Amplia Therapeutics Ltd. The current rsi is 29.63. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Amplia Therapeutics Ltd Daily Relative Strength Index (RSI) ChartAmplia Therapeutics Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Amplia Therapeutics Ltd. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Amplia Therapeutics Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Amplia Therapeutics Ltd Daily Stochastic Oscillator ChartAmplia Therapeutics Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Amplia Therapeutics Ltd. The current cci is -327.30297359.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Amplia Therapeutics Ltd Daily Commodity Channel Index (CCI) ChartAmplia Therapeutics Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Amplia Therapeutics Ltd. The current cmo is -51.31659791.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Amplia Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) ChartAmplia Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Amplia Therapeutics Ltd. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Amplia Therapeutics Ltd Daily Williams %R ChartAmplia Therapeutics Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Amplia Therapeutics Ltd.

Amplia Therapeutics Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Amplia Therapeutics Ltd. The current atr is 0.00431653.

Amplia Therapeutics Ltd Daily Average True Range (ATR) ChartAmplia Therapeutics Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Amplia Therapeutics Ltd. The current obv is -390,644.

Amplia Therapeutics Ltd Daily On-Balance Volume (OBV) ChartAmplia Therapeutics Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Amplia Therapeutics Ltd. The current mfi is 32.74.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Amplia Therapeutics Ltd Daily Money Flow Index (MFI) ChartAmplia Therapeutics Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Amplia Therapeutics Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-09ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-06MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Amplia Therapeutics Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Amplia Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.630
Ma 20Greater thanMa 500.077
Ma 50Greater thanMa 1000.077
Ma 100Greater thanMa 2000.078
OpenGreater thanClose0.070
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Amplia Therapeutics Ltd with someone you think should read this too:
  • Are you bullish or bearish on Amplia Therapeutics Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Amplia Therapeutics Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Amplia Therapeutics Ltd

I send you an email if I find something interesting about Amplia Therapeutics Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Amplia Therapeutics Ltd.

Receive notifications about Amplia Therapeutics Ltd in your mailbox!